Dashboard
1
Weak Long Term Fundamental Strength with an average Return on Equity (ROE) of 3.79%
- Poor long term growth as Operating profit has grown by an annual rate 12.33% of over the last 5 years
- Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -888.56
2
Risky -
3
Below par performance in long term as well as near term
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-23.29%
0%
-23.29%
6 Months
-23.69%
0%
-23.69%
1 Year
-15.1%
0%
-15.1%
2 Years
-28.76%
0%
-28.76%
3 Years
-3.24%
0%
-3.24%
4 Years
-60.44%
0%
-60.44%
5 Years
0%
0%
0.0%
HUTCHMED (China) Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
22.83%
EBIT Growth (5y)
12.33%
EBIT to Interest (avg)
-888.56
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.99
Sales to Capital Employed (avg)
0.69
Tax Ratio
100.00%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
3.79%
Valuation key factors
Factor
Value
P/E Ratio
6
Industry P/E
Price to Book Value
2.14
EV to EBIT
-69.61
EV to EBITDA
-183.11
EV to Capital Employed
-32.38
EV to Sales
2.28
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
37.76%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
Mildly Bearish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
4,917.40
6,560.60
-25.05%
Operating Profit (PBDIT) excl Other Income
-254.50
199.90
-227.31%
Interest
22.40
5.90
279.66%
Exceptional Items
-37.50
-45.10
16.85%
Consolidate Net Profit
297.80
791.50
-62.38%
Operating Profit Margin (Excl OI)
-71.30%
20.70%
-9.20%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is -25.05% vs 96.48% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is -62.38% vs 128.05% in Dec 2023
About HUTCHMED (China) Ltd. 
HUTCHMED (China) Ltd.
Pharmaceuticals & Biotechnology
Hutchison China Meditech Limited is an investment holding company principally engaged in the manufacture and sale of drugs. Along with subsidiaries, the Company operates its business through two segments. The Manufacturing Business segment is engaged in the manufacture and distribution of drug products. The Distribution Business segment provides sales and marketing services to pharmaceutical manufacturers. The Company's products include prescription and over the counter (OTC) pharmaceuticals such as banlangen, fu fang dan shen tablets and shexiang baoxin pills and others, and consumer health products. In addition, the Company also develops targeted therapeutics and immunotherapies for oncology and autoimmune diseases.
Company Coordinates 
Company Details
22Nd Floor Hutchison House, 10 Harcourt Road None : 00000
Registrar Details






